Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity and venture capital firm he founded in 2017, and a Partner at Bridge Builders Collaborative, an early-stage venture firm focused on mental health. He was previously global CEO for Sandoz and Alcon at Novartis Group, where he served on the Executive Committee between 2008 and 2016.  

 Jeff is Chairman of the Board of Directors at MAPS Public Benefit Corporation, which has an FDA-designated breakthrough therapy for PTSD that has completed Phase 3 clinical trials, and also serves on the board of directors of Amneal Pharmaceuticals, a leader in specialty and generic pharmaceuticals with over $2 billion in revenues; 908 Devices (NASDAQ: MASS), a high-growth pioneer in life science diagnostics; and Dorian Therapeutics, a Silicon Valley-based cell therapy biotech spun out of Stanford University. He also serves on several non-profit boards including Education Opens Doors, where he serves as Chairman, the North Texas Food Bank, and YPO of Dallas.  

 Between 2008 and 2016, Jeff served on the Executive Committee of Switzerland-based Novartis Group, first as the global CEO of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharma and biosimilar subsidiary which doubled in value during his tenure, and then as CEO of Texas-based Alcon, Novartis’s $10 billion revenue eye care division, which was spun out from Novartis as a publicly listed firm in 2019. At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 people across more than 160 countries and had leadership responsibility for all functions, regions, and franchises.  

 Prior to these roles, Jeff headed Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS at Novartis Pharmaceuticals, leading a team of over 3,000 people across 65 markets and serving on its Executive Committee, and as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a Senior Director of Strategic Planning & Business Development at Gap Inc. and an Engagement Manager with McKinsey & Co., both in San Francisco.  

 Jeff holds an M.B.A. from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff currently serves as a Board Trustee at Breck School, his high school alma mater in Minneapolis.  

 Jeff previously served on the Board of Directors of AdvaMed, the medical device industry association, Roam Analytics, a Silicon Valley-based artificial intelligence healthcare software firm sold to Parexel in 2020, and Wishbone Medical, a leader in pediatric orthopedic medical devices. He was twice named to Fortune’s “40 under 40” global leaders list and has lived in seven countries on four continents. He is married and lives with his wife and two daughters in Dallas and Manhattan Beach, California and enjoys live music, running, skiing, surfing, Iyengar yoga, meditation, travel, and foreign affairs.

Dan Grossman is a Managing Director & Senior Partner at Boston Consulting Group (BCG), one of the world’s preeminent management consulting firms. He has close to 20 years of experience in BCG’s Health Care Practice Area, working with leading biopharmaceutical and medical technology companies on issues of corporate strategy, pipeline development, and commercializing innovation globally. His experience spans therapeutic areas, with significant depth across major areas of neuroscience. He has served as the head of Learning & Development for BCG in North America, and is responsible for BCG’s portfolio of proprietary data and software tools for the Health Care Practice. Grossman also serves as Treasurer and Executive Committee member of the Board of Trustees of the Lyric Opera of Chicago. He holds a Ph.D. from Princeton University and a B.A. from Harvard College.

Amy Emerson is the chief executive officer (CEO) of MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage company dedicated to changing the way mental health conditions are treated. She became CEO when MAPS PBC was formed in 2014 to develop and commercialize prescription psychedelics, starting with MDMA-assisted therapy for individuals with post-traumatic stress disorder. She has led the company through its successful completion of six Phase 2 studies and two Phase 3 studies, fundraising of approximately $150 million and growth to over 120 employees. Amy has decades of pharmaceutical development and research experience and has brought products from Phase 1 studies through FDA approval. From 1993 to 2009, she worked in various fields including immunology, oncology, and vaccines in roles with increasing levels of responsibility for companies such as Novartis and Chiron. Pursuing her love of science and nature, Amy earned her B.S. in Genetics and Cell Biology from Washington State University in 1992.

Gisselle Acevedo is a trauma-informed Marriage and Family therapist and works with people in traditionally marginalized communities. She has served as CEO and in other executive positions across both philanthropic and for-profit organizations, including AT&T, The Los Angeles Times, Para Los Niños, and Ackerman Institute for the Family.

Gisselle has served on the boards of the Harvard John F. Kennedy School of Government, the Los Angeles Area Chamber of Commerce, the Loyola Law School Social Justice Clinic, Health Net, and Farmers Insurance. She is a Regent Emeritus at Loyola Marymount University, Los Angeles, and the Child and Family Guidance Center in Bridgeport, Connecticut.

Gisselle is a graduate of California Institute of Integral Studies Center for Psychedelic Research Therapies and Research. She holds a master’s degree in Marriage and Family Therapy from Fairfield University and a J.D. from Loyola Law School.

Jason Pyle, M.D., Ph.D., joined Evolve as Managing Director in 2022 to focus his work on the mass mental health crisis and the rampant diseases of despair, which afflict tens of millions of Americans. He is an accomplished biotechnology executive with over twenty years of executive management and technology development experience. He has founded and led successful biotechnology and pharmaceutical firms, including Verdant Pharmaceuticals, Triton Biopharma, Fabric Inc., Sapphire Energy, and Epoc Bioengineering. He is committed to developing healthcare technologies and bringing science-backed healing to the most important problems of our generation. He has received numerous awards for his contributions in biotechnology and his business leadership in the life sciences, including Top 100 Green Executive by Forbes, Top Tech Executive by San Diego Magazine, and National Innovator by the U.S. Department of Energy. He holds several pending and issued patents in the engineering and biological sciences and has worked in diverse cross-discipline areas such as nanofabrication, optical engineering, and structural biology. Jason is a veteran of the U.S. Army and earned an Engineering degree from the University of Arizona. He received both his M.D. and Ph.D. in Molecular and Cellular Physiology from the Stanford University School of Medicine.

Miriam Volat is the Co-Director of the Riverstyx Foundation and Director of Indigenous Medicine Conservation Fund. 

She works personally and professionally to promote health in all systems. Miriam works as a facilitator, educator, and community organizer to increase broad-based community and ecological resilience and decolonize philanthropy. Her work focuses on the intersection of biological and socio-cultural diversity. She has never stopped exploring nutrient cycles and soil ecology, the emphasis of her M.S. work in the U.C. Davis Vegetable Crops Dept. She also has degrees in political science and environmental studies. 

Her life’s work at Riverstyx includes supporting efforts that allow issues stigmatized by society to be worked with in a way that brings healing. This includes supporting composting toilets and human bodies and Indigenous medicine, land, and cultural conservation. Riverstyx is committed to supporting a healthful integration of powerful medicines into society in a way that does no harm.  

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.

Dawn McCollough has overseen clinical trial support functions and clinical trials involving thousands of patients across numerous indications, geographies, and stages of development for nearly 30 years. Dawn has also helped numerous organizations grow from the ground-up and to operationalize key milestone events in both clinical drug development and business.

Dawn started a consulting company in 2018. In addition to her role at MAPS PBC, she provides consultation to a variety of pharmaceutical, biotech, and CRO clients.

Previously, she headed clinical operations functions in start-up Biotech organizations and headed Medical Research Operations (including the Medical Research Team) in Late-Stage Development at Biogen. Prior to that, Dawn was head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics, based in Cambridge, MA. Dawn began her career with Novartis as Global Head of Clinical Trial Governance in Siena, Italy. Throughout the course of her career, she has participated in the development of numerous drug products from concept to approval. In addition to her time spent in the U.S., she has worked extensively in Europe, Canada, Latin America, and Asia. Dawn has been chosen as a top Women’s Leader within previously affiliated organizations.

Dawn has an entrepreneurial spirit and is passionate about developing new options for patients and for people. She enjoys travel and has a very strong connection with animals, nature, and anything outdoors. She toes the line at ultra-marathons about which she knows “the only way out is through” but revels in the journey and enjoys spending time with friends and family.